Alexander E. Perl, MD

home / authors / alexander-e-perl-md

Articles

Highlighting Latest Additions to the Treatment Landscape for AML

May 8th 2019

Alexander E. Perl, MD, discusses the latest advancements in the treatment landscape for patients with acute myeloid leukemia. These advances are driven by 2 factors: a better understanding of the biology of the disease and improving therapeutics to meet that understanding.

Dr. Perl on Survival Improvement With Gilteritinib in FLT3+ AML

Alexander E. Perl, MD

April 12th 2019

Alexander E. Perl, MD, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival in patients with <em>FLT3</em>-mutated acute myeloid leukemia treated with the FLT3 inhibitor gilteritinib.

Using Antibody-Drug Conjugates for Treatment of AML

Alexander E. Perl, MD

November 20th 2018

Alexander E. Perl, MD, discusses the use of antibody-drug conjugates in acute myeloid leukemia. Gemtuzumab ozogamicin has already been approved for this patient population.